Latest Pharma Insights
How To Market An OTC GLP-1 Companion Product In The UK
Exclusive: HBW Insight speaks to the MHRA and ASA about how consumer health companies can legally and compliantly market products designed to support GLP-1 users.
HBW Insight - July 29, 2026
Exclusive: HBW Insight speaks to the MHRA and ASA about how consumer health companies can legally and compliantly market products designed to support GLP-1 users.
HBW Insight - July 29, 2026
Teva Targets Forty Biosimilars As Generics Growth Stalls
Teva is scaling biosimilars into a major growth engine, targeting nearly 40 products and expecting to exceed its $800m 2027 sales goal as conventional generics remain under pressure.
Generics Bulletin - July 29, 2026
Teva is scaling biosimilars into a major growth engine, targeting nearly 40 products and expecting to exceed its $800m 2027 sales goal as conventional generics remain under pressure.
Generics Bulletin - July 29, 2026
GSK’s Ris-Rez Notches Osteosarcoma Win Ahead Of Prostate Phase III Push
The latest osteosarcoma data further strengthen Ris-Rez's late-stage evidence base as GSK advances the ADC across multiple global registrational studies.
Scrip - July 29, 2026
The latest osteosarcoma data further strengthen Ris-Rez's late-stage evidence base as GSK advances the ADC across multiple global registrational studies.
Scrip - July 29, 2026
Feeding Frenzy Looms For Bridion Generics After First US Launches
After the expiry of a key US patent protecting Merck & Co’s Bridion blockbuster, the floodgates have opened for generics, allowing launches into a $1.6bn market – but with more than a dozen firms holding ANDA approvals, competition is set to be fierce.
Generics Bulletin - July 29, 2026
After the expiry of a key US patent protecting Merck & Co’s Bridion blockbuster, the floodgates have opened for generics, allowing launches into a $1.6bn market – but with more than a dozen firms holding ANDA approvals, competition is set to be fierce.
Generics Bulletin - July 29, 2026
What Medtech Makers Need To Know About The EU’s New Packaging Rules
The EU's PPWR starts binding packaging obligations on Aug. 12, and there's no blanket medtech exemption. Contact-sensitive device packaging escapes recyclability and recycled-content grades, but conformity assessment, substance limits, EPR and labeling apply in full.
Medtech Insight - July 29, 2026
The EU's PPWR starts binding packaging obligations on Aug. 12, and there's no blanket medtech exemption. Contact-sensitive device packaging escapes recyclability and recycled-content grades, but conformity assessment, substance limits, EPR and labeling apply in full.
Medtech Insight - July 29, 2026
Brazilian Semaglutide Competition Hots Up With Sandoz-Adalvo Approval
Sandoz has set out plans to launch in Brazil by the end of this year its Adalvo-partnered Owozy version of semaglutide, after local regulator Anvisa granted a marketing authorization.
Generics Bulletin - July 29, 2026
Sandoz has set out plans to launch in Brazil by the end of this year its Adalvo-partnered Owozy version of semaglutide, after local regulator Anvisa granted a marketing authorization.
Generics Bulletin - July 29, 2026
Philips Q2 Profit Masks Flat Underlying Margin As Tariff Refund Does The Heavy Lifting
Philips’ Q2 profit jumped, but almost entirely on a one-off €186m US tariff refund. Stripped out, the company’s underlying margin was roughly flat as inflation and tariffs offset growth — and order intake fell for the first time in six quarters.
Medtech Insight - July 29, 2026
Philips’ Q2 profit jumped, but almost entirely on a one-off €186m US tariff refund. Stripped out, the company’s underlying margin was roughly flat as inflation and tariffs offset growth — and order intake fell for the first time in six quarters.
Medtech Insight - July 29, 2026
Generics Bulletin’s Top 50 Ranking For 2026
This article compiles all the data from Generics Bulletin’s 2026 ranking of the Top 50 companies across the generics and biosimilars industry, including additional details of how the firms’ financial figures compare.
Generics Bulletin - July 29, 2026
This article compiles all the data from Generics Bulletin’s 2026 ranking of the Top 50 companies across the generics and biosimilars industry, including additional details of how the firms’ financial figures compare.
Generics Bulletin - July 29, 2026
NewCo Model For Chinese Assets Entering 2.0 Phase
A NewCo 2.0 phase is developing, shifting to earlier-stage assets, pre-NewCo structures and diversified capital, one investor says. But scarce later-stage assets, regulatory uncertainties and geopolitical risks are likely challenges.
Scrip - July 29, 2026
A NewCo 2.0 phase is developing, shifting to earlier-stage assets, pre-NewCo structures and diversified capital, one investor says. But scarce later-stage assets, regulatory uncertainties and geopolitical risks are likely challenges.
Scrip - July 29, 2026
The Generics Bulletin Top 50, Part Three: Industry Evolution Opens Door To New Players
In the third part of this year’s Generics Bulletin Top 50, we see how industry consolidation and changes in strategy have left gaps in our global ranking for new entrants to fill.
Generics Bulletin - July 29, 2026
In the third part of this year’s Generics Bulletin Top 50, we see how industry consolidation and changes in strategy have left gaps in our global ranking for new entrants to fill.
Generics Bulletin - July 29, 2026
Science Corp. First Commercial Launch Of BCI To Restore Central Vision In Germany, UK
A tiny photovoltaic device placed beneath the retina and paired with smart glasses allows users with advanced macular degeneration to read, play cards and use the subway again. The newly CE-marked device heads toward its first commercial implants in Germany and the UK.
Medtech Insight - July 29, 2026
A tiny photovoltaic device placed beneath the retina and paired with smart glasses allows users with advanced macular degeneration to read, play cards and use the subway again. The newly CE-marked device heads toward its first commercial implants in Germany and the UK.
Medtech Insight - July 29, 2026
GSK’s Ris-Rez Notches Osteosarcoma Win Ahead Of Prostate Phase III Push
The latest osteosarcoma data further strengthen Ris-Rez's late-stage evidence base as GSK advances the ADC across multiple global registrational studies.
Scrip - July 29, 2026
The latest osteosarcoma data further strengthen Ris-Rez's late-stage evidence base as GSK advances the ADC across multiple global registrational studies.
Scrip - July 29, 2026
NewCo Model For Chinese Assets Entering 2.0 Phase
A NewCo 2.0 phase is developing, shifting to earlier-stage assets, pre-NewCo structures and diversified capital, one investor says. But scarce later-stage assets, regulatory uncertainties and geopolitical risks are likely challenges.
Scrip - July 29, 2026
A NewCo 2.0 phase is developing, shifting to earlier-stage assets, pre-NewCo structures and diversified capital, one investor says. But scarce later-stage assets, regulatory uncertainties and geopolitical risks are likely challenges.
Scrip - July 29, 2026
What Medtech Makers Need To Know About The EU’s New Packaging Rules
The EU's PPWR starts binding packaging obligations on Aug. 12, and there's no blanket medtech exemption. Contact-sensitive device packaging escapes recyclability and recycled-content grades, but conformity assessment, substance limits, EPR and labeling apply in full.
Medtech Insight - July 29, 2026
The EU's PPWR starts binding packaging obligations on Aug. 12, and there's no blanket medtech exemption. Contact-sensitive device packaging escapes recyclability and recycled-content grades, but conformity assessment, substance limits, EPR and labeling apply in full.
Medtech Insight - July 29, 2026
Philips Q2 Profit Masks Flat Underlying Margin As Tariff Refund Does The Heavy Lifting
Philips’ Q2 profit jumped, but almost entirely on a one-off €186m US tariff refund. Stripped out, the company’s underlying margin was roughly flat as inflation and tariffs offset growth — and order intake fell for the first time in six quarters.
Medtech Insight - July 29, 2026
Philips’ Q2 profit jumped, but almost entirely on a one-off €186m US tariff refund. Stripped out, the company’s underlying margin was roughly flat as inflation and tariffs offset growth — and order intake fell for the first time in six quarters.
Medtech Insight - July 29, 2026
Science Corp. First Commercial Launch Of BCI To Restore Central Vision In Germany, UK
A tiny photovoltaic device placed beneath the retina and paired with smart glasses allows users with advanced macular degeneration to read, play cards and use the subway again. The newly CE-marked device heads toward its first commercial implants in Germany and the UK.
Medtech Insight - July 29, 2026
A tiny photovoltaic device placed beneath the retina and paired with smart glasses allows users with advanced macular degeneration to read, play cards and use the subway again. The newly CE-marked device heads toward its first commercial implants in Germany and the UK.
Medtech Insight - July 29, 2026
How To Market An OTC GLP-1 Companion Product In The UK
Exclusive: HBW Insight speaks to the MHRA and ASA about how consumer health companies can legally and compliantly market products designed to support GLP-1 users.
HBW Insight - July 29, 2026
Exclusive: HBW Insight speaks to the MHRA and ASA about how consumer health companies can legally and compliantly market products designed to support GLP-1 users.
HBW Insight - July 29, 2026
Teva Targets Forty Biosimilars As Generics Growth Stalls
Teva is scaling biosimilars into a major growth engine, targeting nearly 40 products and expecting to exceed its $800m 2027 sales goal as conventional generics remain under pressure.
Generics Bulletin - July 29, 2026
Teva is scaling biosimilars into a major growth engine, targeting nearly 40 products and expecting to exceed its $800m 2027 sales goal as conventional generics remain under pressure.
Generics Bulletin - July 29, 2026
Feeding Frenzy Looms For Bridion Generics After First US Launches
After the expiry of a key US patent protecting Merck & Co’s Bridion blockbuster, the floodgates have opened for generics, allowing launches into a $1.6bn market – but with more than a dozen firms holding ANDA approvals, competition is set to be fierce.
Generics Bulletin - July 29, 2026
After the expiry of a key US patent protecting Merck & Co’s Bridion blockbuster, the floodgates have opened for generics, allowing launches into a $1.6bn market – but with more than a dozen firms holding ANDA approvals, competition is set to be fierce.
Generics Bulletin - July 29, 2026
Brazilian Semaglutide Competition Hots Up With Sandoz-Adalvo Approval
Sandoz has set out plans to launch in Brazil by the end of this year its Adalvo-partnered Owozy version of semaglutide, after local regulator Anvisa granted a marketing authorization.
Generics Bulletin - July 29, 2026
Sandoz has set out plans to launch in Brazil by the end of this year its Adalvo-partnered Owozy version of semaglutide, after local regulator Anvisa granted a marketing authorization.
Generics Bulletin - July 29, 2026
Generics Bulletin’s Top 50 Ranking For 2026
This article compiles all the data from Generics Bulletin’s 2026 ranking of the Top 50 companies across the generics and biosimilars industry, including additional details of how the firms’ financial figures compare.
Generics Bulletin - July 29, 2026
This article compiles all the data from Generics Bulletin’s 2026 ranking of the Top 50 companies across the generics and biosimilars industry, including additional details of how the firms’ financial figures compare.
Generics Bulletin - July 29, 2026
The Generics Bulletin Top 50, Part Three: Industry Evolution Opens Door To New Players
In the third part of this year’s Generics Bulletin Top 50, we see how industry consolidation and changes in strategy have left gaps in our global ranking for new entrants to fill.
Generics Bulletin - July 29, 2026
In the third part of this year’s Generics Bulletin Top 50, we see how industry consolidation and changes in strategy have left gaps in our global ranking for new entrants to fill.
Generics Bulletin - July 29, 2026
Why SynAct Thinks Resomelagon’s Two Phase II Misses Are A Design Problem, Not A Drug Problem
The efficacy signal has been consistently positive across studies. The problem is a placebo response that keeps outrunning the study design
In Vivo - July 28, 2026
The efficacy signal has been consistently positive across studies. The problem is a placebo response that keeps outrunning the study design
In Vivo - July 28, 2026
As Blockbusters Genericize, Precision Bets Reshape The Autoimmune Pipeline
Precision medicine is coming to autoimmune diseases. Investors and dealmakers are buying in to more powerful, safer treatment prospects in large markets.
In Vivo - July 28, 2026
Precision medicine is coming to autoimmune diseases. Investors and dealmakers are buying in to more powerful, safer treatment prospects in large markets.
In Vivo - July 28, 2026